Background
- The WHO recognizes multiple variant histologies of urothelial carcinoma (vUC), many of which have been associated with poor outcomes compared with UC (UC).
- Prior studies have identified molecular differences between variant vUC and UC through targeted techniques, for example, HER2 gene amplification in micropapillary histology or CDH1 loss is plasmacytoid histology.
- We aimed to explore molecular differences between aggressive vUC and UC using multiplatform profiling.